Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celia...
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
Author: Fierce Biotech
Read Original Article